Nicole Guiso1, Corinne Levy2, Olivier Romain3, Sophie Guillot1, Andreas Werner4, Marie Charlotte Rondeau5, Stéphane Béchet5, Robert Cohen6. 1. Institut Pasteur, Molecular Prevention and Therapy of Human Infections Unit, Paris, France. 2. ACTIV, Association Clinique Thérapeutique Infantile du Val de Marne, Saint Maur des Fossés, France; AFPA, Association Française de Pédiatrie Ambulatoire, Villeneuve les Avignons, France; Université Paris Est, IMRB-GRC GEMINI, Créteil, France; Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, France. Electronic address: corinne.levy@activ-france.fr. 3. ACTIV, Association Clinique Thérapeutique Infantile du Val de Marne, Saint Maur des Fossés, France; Service de pédiatrie et réanimation néonatales, Hôpitaux Universitaires Paris-Sud (HUPS), Antoine Béclère, Clamart, France. 4. AFPA, Association Française de Pédiatrie Ambulatoire, Villeneuve les Avignons, France. 5. ACTIV, Association Clinique Thérapeutique Infantile du Val de Marne, Saint Maur des Fossés, France. 6. ACTIV, Association Clinique Thérapeutique Infantile du Val de Marne, Saint Maur des Fossés, France; AFPA, Association Française de Pédiatrie Ambulatoire, Villeneuve les Avignons, France; Université Paris Est, IMRB-GRC GEMINI, Créteil, France; Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, France; Unité Court Séjour, Petits nourrissons, Service de Néonatalogie, Centre Hospitalier Intercommunal de Créteil, France.
Abstract
BACKGROUND: Increasing incidence of whooping cough (pertussis) has been reported in many countries, attributed to a switch from whole-cell pertussis-containing vaccine (wPV) to acellular PV (aPV) and circulation of the pertactin non-producing Bordetella pertussis. The present study aimed to estimate the duration of immunity conferred by PVs in children in France with data from an ongoing pediatric ambulatory surveillance of pertussis. METHODS: A total of 64 pediatricians throughout France enrolled children with suspected pertussis. A standardized data form was used to collect data on age sex, vaccination status, brand of wPV or aPV and source of infection. Confirmed cases were positive on culture and/or real-time Polymerase Chain Reaction (for B.-non-classified or B. pertussis or B. parapertussis) and/or pertussis serology. RESULTS: Between October 2006 and December 2015, 149 cases of confirmed Bordetella infections were reported, 86 infected with B. pertussis and 55 B. non-classified. Fifteen children (10.1%) were not vaccinated, and 26 (17.4%) were partially vaccinated. The mean age was greater for children who received 4 doses of wPV (11.3±2.2, p<0.001) or a combination of wPV and aPV (10.5±3.3, p<0.001) than only aPV (7.2±2.4years). The mean duration of cough before a visit to a pediatrician was longer for children with wPV or a combination of wPV and aPV than only aPV (23.8±10.1 and 25.0±25.6vs 13.6±10.0days). CONCLUSION: Despite the use of a more sensitive diagnostic method and emergence of pertactin non producing B. pertussis, in France context, aPV-induced immunity still protects against pertussis; however, the mean duration of immunity is about 6 to 7years, compared to 9years for wPV vaccine, after the primary vaccination and one booster (3+1 doses).
BACKGROUND: Increasing incidence of whooping cough (pertussis) has been reported in many countries, attributed to a switch from whole-cell pertussis-containing vaccine (wPV) to acellular PV (aPV) and circulation of the pertactin non-producing Bordetella pertussis. The present study aimed to estimate the duration of immunity conferred by PVs in children in France with data from an ongoing pediatric ambulatory surveillance of pertussis. METHODS: A total of 64 pediatricians throughout France enrolled children with suspected pertussis. A standardized data form was used to collect data on age sex, vaccination status, brand of wPV or aPV and source of infection. Confirmed cases were positive on culture and/or real-time Polymerase Chain Reaction (for B.-non-classified or B. pertussis or B. parapertussis) and/or pertussis serology. RESULTS: Between October 2006 and December 2015, 149 cases of confirmed Bordetella infections were reported, 86 infected with B. pertussis and 55 B. non-classified. Fifteen children (10.1%) were not vaccinated, and 26 (17.4%) were partially vaccinated. The mean age was greater for children who received 4 doses of wPV (11.3±2.2, p<0.001) or a combination of wPV and aPV (10.5±3.3, p<0.001) than only aPV (7.2±2.4years). The mean duration of cough before a visit to a pediatrician was longer for children with wPV or a combination of wPV and aPV than only aPV (23.8±10.1 and 25.0±25.6vs 13.6±10.0days). CONCLUSION: Despite the use of a more sensitive diagnostic method and emergence of pertactin non producing B. pertussis, in France context, aPV-induced immunity still protects against pertussis; however, the mean duration of immunity is about 6 to 7years, compared to 9years for wPV vaccine, after the primary vaccination and one booster (3+1 doses).
Authors: R Solano; A V Sanchez-Callejas; M I Alvarez-Ibañez; M Sandiumenge-Durán; M I Fernández-San-Martín Journal: Epidemiol Infect Date: 2019-08-20 Impact factor: 2.451
Authors: Marion Debin; Titouan Launay; Louise Rossignol; Fatima Ait El Belghiti; Sylvain Brisse; Sophie Guillot; Nicole Guiso; Daniel Levy-Bruhl; Lore Merdrignac; Julie Toubiana; Thierry Blanchon; Thomas Hanslik Journal: Euro Surveill Date: 2022-04